Ask AI
ProCE Banner Activity

KRAS G12C–Mutated NSCLC: Addressing Unmet Needs and Emerging Therapeutic Insights

Clinical Thought

Despite the availability of approved KRAS G12C inhibitors for advanced NSCLC, resistance and limited durability of response remain significant clinical challenges. This commentary reviews emerging data on next-generation KRAS-targeted therapies and immunotherapy combinations that may shape the future of precision medicine in KRAS-mutated lung cancer.

Released: June 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Lilly.

Genentech, a member of the Roche Group

Lilly

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with NSCLC who may be eligible for treatment with next-generation KRAS G12C–targeted therapies when they become available 

  • Consider how next-generation KRAS G12C–targeted agents in late-phase clinical trials might be integrated into real-world clinical practice for patients with NSCLC 

  • Discuss with colleagues and patients ongoing advances in targeting KRAS G12C for solid tumors

Financial Disclosures

Primary Author

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech, Jazz, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer, Summit, Turning Point Therapeutics, Voronoi; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb.

Luis Paz-Ares, MD, PhD: honoraria: Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Lilly, Merck Serono, Mirati, Novartis, Pfizer, PharmaMar, Roche/Genentech, Sanofi, Takeda; founder and board member: ALTUM Sequencing, Stab Therapeutics; research funding (to Institution): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, PharmaMar; speaker: Bristol Myers Squibb, Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Roche/Genentech.